Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth


  • Products Id :- GBIHC422MR
  • |
  • Pages: 192
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Global Cardiovascular Disease Market to 2022-Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth

Summary

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market with the advent of statins such as Lipitor, the best-selling drug of all time, which produce marked reductions in cholesterol levels. More recently, the commonly used direct factor Xa inhibitors which produce anti-coagulant effects, have been made available for oral administration and the advent of PCSK9 inhibitors provide a viable alternative dyslipidemia treatment for when statins are unsuitable or inefficient. There are currently 1368 pipeline drugs within the cardiovascular disease market, the largest therapy area being thrombosis, with 406 pipeline products indicated for treatment or prevention of thrombotic events.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.

Scope

Analysis of innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events.

A brief introduction to CVD, including symptoms, pathophysiology, and an overview of pharmacotherapy for the key diseases.

Identification of key marketed products, with a focus on historical and forecast sales patterns and an overview of each drug's mechanism of action.

Comprehensive review of the pipeline, analyzed on the basis of stage of development, molecule type and molecular target.

In-depth market forecasting from 2015 to 2022. The forecasts will provide an understanding of how epidemiology trends, new drug entries and drug patent expirations will influence market value.

Identification and assessment of key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as a sales forecast for these products.

Identification of the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent these companies are on CVD product revenue. In addition, analysis determines the primary factors that will drive market growth for the key companies.

Assessment of the licensing and co-development deal landscape for CVD therapies.

Reasons to Buy

This report will allow you to

Understand the current clinical and commercial landscape through a comprehensive analysis of the innovation in the CVD market in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include hypertension, dyslipidemia and thrombotic events

Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns and an overview of the drug's mechanism of action.

Analyze the CVD pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at CVD clinical trials as to provide an insight into the risk associated with attempting to bring CVD pipeline drugs.

Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patents expirations will influence market value.

Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as a sales forecast for these products.

Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from CVD products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.

Identify commercial opportunities in the CVD deals landscape by analyzing trends in licensing and co-development deals.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 11

2.1 Therapy Area Introduction 11

2.2 Symptoms 11

2.3 Etiology, Pathophysiology, Comorbidities and Complications 12

2.3.1 Hypertension 12

2.3.2 Dyslipidemia 13

2.3.3 Thrombotic events 15

2.4 Diagnosis 17

2.4.1 Hypertension 17

2.4.2 Dyslipidemia 17

2.4.3 Thrombotic events 18

2.5 Prognosis 18

2.6 Epidemiology Patterns and Forecasts-Prevalence and Patient Segmentation 19

2.6.1 Hypertension 20

2.6.2 Dyslipidemia 21

2.6.3 Thrombotic events 21

2.7 Treatment 22

2.7.1 Thiazide Diuretics 23

2.7.2 Angiotensin Converting Enzyme Inhibitors 24

2.7.3 Angiotensin Receptor Blockers 25

2.7.4 Calcium Channel Blockers 25

2.7.5 Statins 25

2.7.6 Anticoagulants 26

2.7.7 Antiplatelet Drugs 27

2.7.8 Beta-adrenoceptor antagonists (Beta blockers) 27

2.7.9 Other Drugs 28

3 Key Marketed Products 29

3.1 Overview 29

3.2 Crestor (rosuvastatin)-AstraZeneca 29

3.3 Zetia (ezetimibe)-Merck & Co 30

3.4 Lipitor (atorvastatin)-Pfizer 32

3.5 Praluent (alirocumab)-Sanofi 34

3.6 Xarelto (rivaroxaban)-Bayer 35

3.7 Eliquis (apixaban)-Bristol-Myers Squibb and Pfizer 37

3.8 Plavix (clopidogrel)-Sanofi 38

3.9 Brilinta (ticagrelor)-AstraZeneca 40

3.10 Entresto (valsartan plus sacubitril)-Novartis 41

3.11 Benicar (olmesartan medoxomil)-Daiichi Sankyo 43

3.12 Conclusion 44

4 Pipeline Landscape Assessment 46

4.1 Overview 46

4.2 Pipeline Development Landscape 46

4.3 Molecular Targets in the Pipeline 49

4.4 Clinical Trials 53

4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 53

4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 57

4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 60

4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 63

4.5 Conclusion 66

5 Multi-Scenario Market Forecast to 2022 67

5.1 Overall Market Size 67

5.2 Generic Penetration 69

5.3 Revenue Forecast by Molecular Target 70

5.3.1 Coagulation Cascade 71

5.3.2 P2Y12 Receptors 71

5.3.3 Beta 1 Adrenergic Receptors 72

5.3.4 PCSK9 Inhibitors 73

5.3.5 HMG-CoA Reductase Inhibitors (statins) 74

5.3.6 Renin angiotensin system (RAS) 75

5.3.7 Revenue and Market Share Analysis by Company 75

5.3.8 Assessment of Key Pipeline Products 86

6 Company Analysis and Positioning 93

6.1 Company Landscape 94

6.2 Marketed and Pipeline Portfolio Analysis 95

7 Strategic Consolidations 99

7.1 Licensing Deals 99

7.1.1 Deals by Region, Year and Value 99

7.1.2 Deals by Stage of Development and Value 101

7.1.3 Deals by Molecule Type, Mechanism of Action and Value 102

7.1.4 Licensing Deals Valued Above $200m 104

7.2 Co-development Deals 106

7.2.1 Deals by Region, Year and Value 106

7.2.2 Deals by Stage of Development and Value 107

7.2.3 Deals by Molecule Type, Mechanism of Action and Value 107

7.2.4 Co-development Deals Valued Above $100m 109

8 Appendix 111

8.1 References 111

8.2 Tables of All Pipeline Products 116

8.3 Table of Epidemiology Forecast 186

8.4 Abbreviations 188

8.5 Methodology 189

8.5.1 Coverage 190

8.5.2 Secondary Research 190

8.5.3 Market Size and Revenue Forecasts 190

8.5.4 Pipeline Analysis 191

8.5.5 Competitive Landscape 191

8.6 Contact Us 191

8.7 Disclaimer 191

1.2 List of Figures

Figure 1: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Hypertension, 2015-2022 20

Figure 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Dyslipidemia, 2015-2022 21

Figure 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology Patterns for Acute Coronary Syndrome, Ischemic Stroke and Venous Thromboembolism, 2015-2022 22

Figure 4: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Crestor ($bn), 2006-2022 30

Figure 5: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Zetia ($bn), 2006-2022 32

Figure 6: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Lipitor ($bn), 2006-2022 34

Figure 7: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Praluent ($bn), 2006-2022 35

Figure 8: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Xarelto ($bn), 2006-2022 37

Figure 9: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Eliquis ($bn), 2006-2022 38

Figure 10: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Plavix ($bn), 2006-2022 40

Figure 11: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Brilinta ($bn), 2006-2022 41

Figure 12: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Entresto ($bn), 2006-2022 42

Figure 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue for Benicar ($bn), 2006-2022 44

Figure 14: Cardiovascular Disease Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 46

Figure 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Cardiovascular Diseases by Stage of Development, Molecule Type and Program Type, 2016 47

Figure 16: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Stage of Development, 2016 48

Figure 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecule Type, 2016 49

Figure 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target, 2016 51

Figure 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 52

Figure 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline for Key Cardiovascular Disease Indications by Molecular Target, 2016 53

Figure 21: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 54

Figure 22: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 55

Figure 23: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 56

Figure 24: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 57

Figure 25: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 57

Figure 26: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 58

Figure 27: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 59

Figure 28: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 60

Figure 29: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016 60

Figure 30: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016 61

Figure 31: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 62

Figure 32: Cardiovascular Disease Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 63

Figure 33: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2016 64

Figure 34: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 64

Figure 35: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016 65

Figure 36: Cardiovascular Disease Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 66

Figure 37: Cardiovascular Disease Therapeutics Market, Global, Market Size ($bn), 2015-2022 67

Figure 38: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2015-2022 69

Figure 39: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Targeting Elements of the Coagulation Cascade ($bn), 2015-2022 71

Figure 40: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for P2Y12 Inhibitors ($bn), 2015-2022 72

Figure 41: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Beta Blockers ($bn), 2015-2022 73

Figure 42: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for PCSK9 Inhibitors ($m), 2015-2022 74

Figure 43: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for HMG-CoA Inhibitors ($bn), 2015-2022 74

Figure 44: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Drugs Acting on RAS ($bn), 2015-2022 75

Figure 45: Cardiovascular Disease Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 78

Figure 46: Cardiovascular Disease Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015-2022 79

Figure 47: Cardiovascular Disease Therapeutics Market, Global, Revenues by Product Type, 2015-2022 80

Figure 48: Cardiovascular Disease Therapeutics Market, Global, Sanofi Annual Revenue Forecast ($bn), 2015-2022 81

Figure 49: Cardiovascular Disease Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2015-2022 82

Figure 50: Cardiovascular Disease Therapeutics Market, Global, Novartis Annual Revenue Forecast ($bn), 2015-2022 83

Figure 51: Cardiovascular Disease Therapeutics Market, Global, Bayer Annual Revenue Forecast ($bn), 2015-2022 84

Figure 52: Cardiovascular Disease Therapeutics Market, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022 85

Figure 53: Cardiovascular Disease Therapeutics Market, Global, Merck Annual Revenue Forecast ($bn), 2015-2022 86

Figure 54: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Bococizumab ($m), 2018-2022 87

Figure 55: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Betrixaban ($m), 2017-2022 88

Figure 56: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Anacetrapib ($m), 2018-2022 89

Figure 57: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Volanesorsen ($m), 2017-2022 90

Figure 58: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for Vericiguat ($m), 2018-2022 91

Figure 59: Cardiovascular Disease Therapeutics Market, Global, Revenue Forecast for ETC-1002 ($m), 2018-2022 92

Figure 60: Cardiovascular Disease Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 93

Figure 61: Cardiovascular Disease Therapeutics Market, Global, Companies by Type, 2016 95

Figure 62: Cardiovascular Disease Therapeutics Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Cardiovascular Specialization, 2016 96

Figure 63: Cardiovascular Disease Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Cardiovascular Disease, 2015-2022 97

Figure 64: Cardiovascular Disease Therapeutics Market, Global, Top Six Companies, Proportion of Total Company Revenue Attributed to Cardiovascular Disease ($bn), 2015-2022 98

Figure 65: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006-2016 100

Figure 66: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Indication, 2006-2016 101

Figure 67: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006-2016 102

Figure 68: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016 103

Figure 69: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006-2016 106

Figure 70: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Indication, 2006-2016 107

Figure 71: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 108

1.1 List of Tables

Table 1: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category 17

Table 2: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, 2016 20

Table 3: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Crestor, 2016 29

Table 4: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Zetia, 2016 31

Table 5: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Lipitor, 2016 33

Table 6: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Praluent, 2016 34

Table 7: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Xarelto, 2016 36

Table 8: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Eliquis, 2016 37

Table 9: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Plavix, 2016 39

Table 10: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Brilinta, 2016 40

Table 11: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Entresto, 2016 41

Table 12: Cardiovascular Disease Therapeutics Market, Global, Approved Indications for Benicar, 2016 43

Table 13: Cardiovascular Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022 68

Table 14: Cardiovascular Disease Therapeutics Market, Global, Usage of Generics Across Key Indications, 2015 70

Table 15: Cardiovascular Disease Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022 76

Table 16: Cardiovascular Disease Therapeutics Market, Global, Licensing Deals, 2006-2016 104

Table 17: Cardiovascular Disease Therapeutics Market, Global, Co-development Deals, 2006-2016 109

Table 18: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Discovery, 2016 116

Table 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Preclinical, 2016 126

Table 20: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2016 165

Table 21: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase I, 2016 165

Table 22: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase II, 2016 170

Table 23: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Phase III, 2016 178

Table 24: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Pre-registration, 2016 184

Table 25: Cardiovascular Disease Therapeutics Market, Global, Pipeline Products, Unknown, 2016 186

Table 26: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Hypertension, 2015-2022 186

Table 27: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Dyslipidemia, 2015-2022 187

Table 28: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Acute Coronary Syndrome, 2015-2022 187

Table 29: Cardiovascular Disease Therapeutics Market, Prevalence Patterns for Ischemic Stroke, 2015-2022 187

Table 30: Cardiovascular Disease Therapeutics Market, Incident Cases for Venous Thromboembolism, 2015-2022 188

Table 31: Abbreviations 188

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

select a license

Single User License
USD 4995 INR 321428
Site License
USD 9990 INR 642857
Corporate User License
USD 14985 INR 964285

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com